Skip to main content
. 2022 Mar 10;9:157–170. doi: 10.2147/JHC.S353956

Figure 1.

Figure 1

Flow diagram showing exclusion of patients with advanced hepatocellular carcinoma (HCC) who received regorafenib combined with sintilimab (rego-sintilimab) or regorafenib in a second-line setting.